Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis
Haemophilia · 2026
DOI: 10.1111/hae.70203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Hermann Eichler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Haemostaseology and Transfusion Medicine, Saarland University and Saarland University Hospital, Homburg, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Thrombelastography, Blood Coagulation, Hemophilia A. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
Background
Rotational thromboelastometry (ROTEM) aims to measure the coagulation potential in whole blood. Concizumab, an anti‐tissue factor pathway inhibitor (TFPI) antibody for prophylaxis in haemophilia, enhances tissue factor (TF)‐initiated coagulation by preventing inhibition of activated factor X (FXa), thus increasing thrombin generation.
Objectives
To evaluate a modified ROTEM assay for monitoring patients on concizumab prophylaxis.
Methods
The TF reagent (r_exTEM) was diluted 50,000‐fold to make the ROTEM assay sensitive to haemophilia and to concizumab. The effect of concizumab was evaluated in the modified ROTEM in haemophilia A (HA)‐like blood (normal blood with added anti‐FVIII antibody). ROTEM analysis was performed in blood from patients participating in the explorer7/8 trials during 24 weeks of concizumab prophylaxis. Rotrol N plasma was used as quality control.
Results
In vitro experiments showed concizumab concentration‐dependent reduction in clot time (CT) and increase in clot development (α‐angle) in HA‐like blood. At three of four clinical sites, CT and clot development were stable, variance of the control plasma was ≤12.4% and TF content of the diluted reagent (r_exTEM) was consistent. At these three sites, the correlation between CT versus concizumab exposure, free TFPI and thrombin generation assay parameters was weak (‐0.508 to +0.359). Prothrombin time positively correlated with CT (0.523) and negatively correlated with α‐angle (‐0.659).
Conclusion
Due to the poor correlation between ROTEM parameters, concizumab exposure, free TFPI and thrombin generation parameters and the lack of consistent and reliable performance of the modified ROTEM assay, it cannot be recommended for general monitoring of patients on concizumab prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Haemostaseology and Transfusion Medicine, Saarland University and Saarland University Hospital, Homburg, Germany.
- Department of Haematology, La Paz University Hospital, Coagulopathies and Disorders of Haemostasis Group IdiPaz, Madrid, Spain.
- KD Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.
- Health Services Laboratory, London, UK.
- Department of Clinical Chemistry and Pharmacology, University and Regional Laboratories Region Skåne, Malmö, Sweden.
- Novo Nordisk A/S, Måløv, Denmark.
Förderung
- Novo Nordisk A/S
Zitieren
APA
Eichler, H., Butta, N. V., Riddell, A., Augustsson, C., Kjalke, M., Jensen, K., Paramo-Florencio, A., Astermark, J., Chowdary, P., & Jiménez-Yuste, V. (2026). Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis. Haemophilia. https://doi.org/10.1111/hae.70203
Vancouver
Eichler H, Butta NV, Riddell A, Augustsson C, Kjalke M, Jensen K, et al. Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis. Haemophilia. 2026. doi:10.1111/hae.70203
BibTeX
@article{Eichler2026,
author = {Eichler, Hermann and Butta, Nora V and Riddell, Anne and Augustsson, Cecilia and Kjalke, Marianne and Jensen, Kasper and Paramo-Florencio, Andrea and Astermark, Jan and Chowdary, Pratima and Jiménez-Yuste, Victor},
title = {Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70203}
}
EUVIMED